Published in J Infect Dis on January 01, 1993
Diagnosis of lyme borreliosis. Clin Microbiol Rev (2005) 4.48
Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J Exp Med (1993) 2.96
Efficient targeted mutagenesis in Borrelia burgdorferi. J Bacteriol (2000) 2.89
The Lyme disease agent exploits a tick protein to infect the mammalian host. Nature (2005) 2.82
Spirochaetal lipoproteins and pathogenesis. Microbiology (2000) 2.30
Active and passive immunity against Borrelia burgdorferi decorin binding protein A (DbpA) protects against infection. Infect Immun (1998) 2.29
Decorin-binding protein of Borrelia burgdorferi is encoded within a two-gene operon and is protective in the murine model of Lyme borreliosis. Infect Immun (1998) 2.23
Limited surface exposure of Borrelia burgdorferi outer surface lipoproteins. Proc Natl Acad Sci U S A (1996) 1.90
A family of surface-exposed proteins of 20 kilodaltons in the genus Borrelia. Infect Immun (1994) 1.89
Outer membrane proteins of pathogenic spirochetes. FEMS Microbiol Rev (2004) 1.87
Borrelia burgdorferi changes its surface antigenic expression in response to host immune responses. Infect Immun (2004) 1.82
Complement-mediated serum sensitivity among spirochetes that cause Lyme disease. Infect Immun (1997) 1.79
An OspB mutant of Borrelia burgdorferi has reduced invasiveness in vitro and reduced infectivity in vivo. Infect Immun (1993) 1.79
Directed insertion of a selectable marker into a circular plasmid of Borrelia burgdorferi. J Bacteriol (1996) 1.78
Access of antibody or trypsin to an integral outer membrane protein (P66) of Borrelia burgdorferi is hindered by Osp lipoproteins. Infect Immun (1999) 1.74
Molecular analysis of genes encoding outer surface protein C (OspC) of Borrelia burgdorferi sensu lato: relationship to ospA genotype and evidence of lateral gene exchange of ospC. J Clin Microbiol (1995) 1.67
Molecular characterization of a 6.6-kilodalton Borrelia burgdorferi outer membrane-associated lipoprotein (lp6.6) which appears to be downregulated during mammalian infection. Infect Immun (1997) 1.57
Retracted Localization of BmpA on the exposed outer membrane of Borrelia burgdorferi by monospecific anti-recombinant BmpA rabbit antibodies. Infect Immun (2004) 1.56
Altered stationary-phase response in a Borrelia burgdorferi rpoS mutant. J Bacteriol (2000) 1.49
Borrelia burgdorferi mutant lacking Osp: biological and immunological characterization. Infect Immun (1995) 1.49
Elongated versions of Vlp surface lipoproteins protect Mycoplasma hyorhinis escape variants from growth-inhibiting host antibodies. Infect Immun (1997) 1.43
Identification and characterization of a surface-exposed, 66-kilodalton protein from Borrelia burgdorferi. Infect Immun (1995) 1.41
Comparative analysis and immunological characterization of the Borrelia Bdr protein family. Infect Immun (1999) 1.40
The 39-kilodalton protein of Borrelia burgdorferi: a target for bactericidal human monoclonal antibodies. Infect Immun (1993) 1.38
Antigenic stability of Borrelia burgdorferi during chronic infections of immunocompetent mice. Infect Immun (1993) 1.31
A surface-exposed region of a novel outer membrane protein (P66) of Borrelia spp. is variable in size and sequence. J Bacteriol (1998) 1.30
Development of destructive arthritis in vaccinated hamsters challenged with Borrelia burgdorferi. Infect Immun (1994) 1.30
A bactericidal antibody to Borrelia burgdorferi is directed against a variable region of the OspB protein. Infect Immun (1994) 1.24
Differential immune responses to Borrelia burgdorferi in European wild rodent species influence spirochete transmission to Ixodes ricinus L. (Acari: Ixodidae). Infect Immun (1994) 1.24
Identification of Borrelia burgdorferi outer surface proteins. Infect Immun (2006) 1.23
Characterization of the physiological requirements for the bactericidal effects of a monoclonal antibody to OspB of Borrelia burgdorferi by confocal microscopy. Infect Immun (1997) 1.19
Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi. Infect Immun (1995) 1.18
Seroprotective groups among isolates of Borrelia burgdorferi. Infect Immun (1993) 1.14
Sensitivity and specificity of the borreliacidal-antibody test during early Lyme disease: a "gold standard"? Clin Diagn Lab Immunol (1996) 1.14
Abilities of OspA proteins from different seroprotective groups of Borrelia burgdorferi to protect hamsters from infection. Infect Immun (1995) 1.13
Molecular analysis of neutralizing epitopes on outer surface proteins A and B of Borrelia burgdorferi. Infect Immun (1995) 1.10
Cholesterol lipids of Borrelia burgdorferi form lipid rafts and are required for the bactericidal activity of a complement-independent antibody. Cell Host Microbe (2010) 1.09
Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters. Clin Diagn Lab Immunol (2005) 1.06
Sera from OspA-vaccinated dogs, but not those from tick-infected dogs, inhibit in vitro growth of Borrelia burgdorferi. J Clin Microbiol (1995) 1.05
In vitro and in vivo neutralization of the relapsing fever agent Borrelia hermsii with serotype-specific immunoglobulin M antibodies. Infect Immun (2001) 1.05
Comparison of different strains of Borrelia burgdorferi sensu lato used as antigens in enzyme-linked immunosorbent assays. J Clin Microbiol (1994) 1.04
Genetic stability of Borrelia burgdorferi recovered from chronically infected immunocompetent mice. Infect Immun (1994) 1.03
Ability of the borreliacidal antibody test to confirm lyme disease in clinical practice. Clin Diagn Lab Immunol (2002) 0.99
Use of the Cre-lox recombination system to investigate the lp54 gene requirement in the infectious cycle of Borrelia burgdorferi. Infect Immun (2010) 0.93
Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi. Antimicrob Agents Chemother (1993) 0.91
Detection of anti-Borrelia burgdorferi antibody responses with the borreliacidal antibody test, indirect fluorescent-antibody assay performed by flow cytometry, and western immunoblotting. Clin Diagn Lab Immunol (1996) 0.91
Host-pathogen interactions in the immunopathogenesis of Lyme disease. J Clin Immunol (1997) 0.91
Efficacy of an evernimicin (SCH27899) in vitro and in an animal model of Lyme disease. Antimicrob Agents Chemother (2001) 0.83
In vitro activities of the everninomicin SCH 27899 and other newer antimicrobial agents against Borrelia burgdorferi. Antimicrob Agents Chemother (1999) 0.83
Neutralization of gamma interferon augments borreliacidal antibody production and severe destructive Lyme arthritis in C3H/HeJ mice. Clin Diagn Lab Immunol (2004) 0.80
Purification of Borrelia burgdorferi outer surface protein A (OspA) and analysis of antibody binding domains. Clin Diagn Lab Immunol (1994) 0.80
Detection of borreliacidal antibodies in Lyme borreliosis patient sera containing antimicrobial agents. Clin Diagn Lab Immunol (1999) 0.78
Single exposure of mice to Borrelia burgdorferi elicits immunoglobulin G antibodies characteristic of secondary immune response without production of interleukin-4 by immune T cells. Infect Immun (1995) 0.78
Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model. PLoS One (2013) 0.78
Outer membrane proteins BB0405 and BB0406 are immunogenic but only BB0405 is required for Borrelia burgdorferi infection. Infect Immun (2016) 0.75
In vitro assessment of antiborrelial activity of OspA vaccine sera. Clin Diagn Lab Immunol (2002) 0.75
Lyme disease-a tick-borne spirochetosis? Science (1982) 27.50
The spirochetal etiology of Lyme disease. N Engl J Med (1983) 21.59
Isolation and cultivation of Lyme disease spirochetes. Yale J Biol Med (1985) 20.49
Spirochetes isolated from the blood of two patients with Lyme disease. N Engl J Med (1983) 11.15
Lyme disease spirochetes and ixodid tick spirochetes share a common surface antigenic determinant defined by a monoclonal antibody. Infect Immun (1983) 9.60
Heterogeneity of major proteins in Lyme disease borreliae: a molecular analysis of North American and European isolates. J Infect Dis (1985) 7.69
Folding dynamics and mechanism of beta-hairpin formation. Nature (1997) 7.30
A Borrelia-specific monoclonal antibody binds to a flagellar epitope. Infect Immun (1986) 6.80
Variation in a major surface protein of Lyme disease spirochetes. Infect Immun (1984) 6.68
Molecular analysis of linear plasmid-encoded major surface proteins, OspA and OspB, of the Lyme disease spirochaete Borrelia burgdorferi. Mol Microbiol (1989) 6.51
Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes. Cell (1997) 6.36
Biology of Borrelia species. Microbiol Rev (1986) 6.03
Linear plasmids of the bacterium Borrelia burgdorferi have covalently closed ends. Science (1987) 5.80
Variable major proteins of Borrellia hermsii. J Exp Med (1982) 5.62
Natural Distribution of the Ixodes dammini spirochete. Science (1983) 5.24
Antigenic variability of Borrelia burgdorferi. Ann N Y Acad Sci (1988) 5.02
Spirochetes in Ixodes dammini and mammals from Connecticut. Am J Trop Med Hyg (1983) 4.86
Low-passage-associated proteins of Borrelia burgdorferi B31: characterization and molecular cloning of OspD, a surface-exposed, plasmid-encoded lipoprotein. Infect Immun (1992) 4.42
Transposition of structural genes to an expression sequence on a linear plasmid causes antigenic variation in the bacterium Borrelia hermsii. Nature (1985) 4.41
Megabase-sized linear DNA in the bacterium Borrelia burgdorferi, the Lyme disease agent. Proc Natl Acad Sci U S A (1989) 4.38
Chlamydia trachomatis has penicillin-binding proteins but not detectable muramic acid. J Bacteriol (1982) 4.33
Antibodies of patients with Lyme disease to components of the Ixodes dammini spirochete. J Clin Invest (1983) 4.08
Antigenic variation is associated with DNA rearrangements in a relapsing fever Borrelia. Cell (1985) 3.78
The cryptic ospC gene of Borrelia burgdorferi B31 is located on a circular plasmid. Infect Immun (1993) 3.50
A single recombinant plasmid expressing two major outer surface proteins of the Lyme disease spirochete. Science (1985) 3.42
Organization of genes encoding two outer membrane proteins of the Lyme disease agent Borrelia burgdorferi within a single transcriptional unit. Infect Immun (1986) 3.39
Antibody-resistant mutants of Borrelia burgdorferi: in vitro selection and characterization. J Exp Med (1992) 3.30
Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry (1993) 3.24
Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J Exp Med (1993) 2.96
Erythema chronicum migrans--a tickborne spirochetosis. Acta Trop (1983) 2.85
Clonal polymorphisms of outer membrane protein OspB of Borrelia burgdorferi. Infect Immun (1989) 2.76
DNA characterization of the spirochete that causes Lyme disease. J Clin Microbiol (1984) 2.71
Heterogeneity of outer membrane proteins in Borrelia burgdorferi: comparison of osp operons of three isolates of different geographic origins. Infect Immun (1992) 2.67
Cloning of 18S and 25S rDNAs from the pathogenic fungus Cryptococcus neoformans. J Bacteriol (1989) 2.55
The western black-legged tick, Ixodes pacificus: a vector of Borrelia burgdorferi. Am J Trop Med Hyg (1985) 2.50
Linear- and circular-plasmid copy numbers in Borrelia burgdorferi. J Bacteriol (1992) 2.45
High- and low-infectivity phenotypes of clonal populations of in vitro-cultured Borrelia burgdorferi. Infect Immun (1995) 2.39
Polymorphisms of major surface proteins of Borrelia burgdorferi. Zentralbl Bakteriol Mikrobiol Hyg A (1986) 2.33
The Motor Activity Log-28: assessing daily use of the hemiparetic arm after stroke. Neurology (2006) 2.29
Outer surface protein A (OspA) from the Lyme disease spirochete, Borrelia burgdorferi: high level expression and purification of a soluble recombinant form of OspA. Protein Expr Purif (1990) 2.23
Linear plasmids of Borrelia burgdorferi have a telomeric structure and sequence similar to those of a eukaryotic virus. J Bacteriol (1991) 2.15
Neuroborreliosis during relapsing fever: review of the clinical manifestations, pathology, and treatment of infections in humans and experimental animals. Clin Infect Dis (1998) 2.15
Absence of lipopolysaccharide in the Lyme disease spirochete, Borrelia burgdorferi. Infect Immun (1987) 2.15
Variable major proteins of Borrelia hermsii. Epitope mapping and partial sequence analysis of CNBr peptides. J Exp Med (1985) 2.12
Enzyme-linked immunosorbent assays for Lyme disease: reactivity of subunits of Borrelia burgdorferi. J Infect Dis (1989) 2.12
Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc Natl Acad Sci U S A (1997) 2.11
Lipoproteins of Borrelia burgdorferi and Treponema pallidum activate cachectin/tumor necrosis factor synthesis. Analysis using a CAT reporter construct. J Immunol (1991) 2.09
An outbreak of giardiasis in a group of campers. Am J Trop Med Hyg (1976) 2.04
Submillisecond kinetics of protein folding. Curr Opin Struct Biol (1997) 2.01
The relapsing fever agent Borrelia hermsii has multiple copies of its chromosome and linear plasmids. Genetics (1992) 2.00
Role of attached lipid in immunogenicity of Borrelia burgdorferi OspA. Infect Immun (1993) 1.98
A flagella-less mutant of Borrelia burgdorferi. Structural, molecular, and in vitro functional characterization. J Clin Invest (1991) 1.95
A family of surface-exposed proteins of 20 kilodaltons in the genus Borrelia. Infect Immun (1994) 1.89
Juxtaposition of expressed variable antigen genes with a conserved telomere in the bacterium Borrelia hermsii. Proc Natl Acad Sci U S A (1990) 1.87
Vaginal isolates of Staphylococcus aureus associated with toxic shock syndrome. Infect Immun (1981) 1.84
Emerging bacterial zoonotic and vector-borne diseases. Ecological and epidemiological factors. JAMA (1996) 1.82
An OspB mutant of Borrelia burgdorferi has reduced invasiveness in vitro and reduced infectivity in vivo. Infect Immun (1993) 1.79
Nucleotide sequence and analysis of the gene in Borrelia burgdorferi encoding the immunogenic P39 antigen. FEMS Microbiol Lett (1994) 1.77
In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies. J Clin Microbiol (1992) 1.75
Immunochemical analysis of Lyme disease spirochetes. Yale J Biol Med (1985) 1.74
Access of antibody or trypsin to an integral outer membrane protein (P66) of Borrelia burgdorferi is hindered by Osp lipoproteins. Infect Immun (1999) 1.74
Expert advice and patient expectations: laboratory testing and antibiotics for Lyme disease. JAMA (1998) 1.73
Variability of a bacterial surface protein and disease expression in a possible mouse model of systemic Lyme borreliosis. J Exp Med (1994) 1.73
Properties of penicillin-binding proteins in Neisseria gonorrhoeae. Antimicrob Agents Chemother (1981) 1.72
Isolation and characterization of the Lyme disease spirochete from the skin of patients with erythema chronicum migrans. J Am Acad Dermatol (1985) 1.71
Antigenic variation and strain heterogeneity in Borrelia spp. Res Microbiol (1993) 1.60
Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer. Cancer Res (1999) 1.57
Fast events in protein folding. Structure (1996) 1.56
Subtelomeric expression regions of Borrelia hermsii linear plasmids are highly polymorphic. Mol Microbiol (1992) 1.55
Cloning and sequence analysis of linear plasmid telomeres of the bacterium Borrelia burgdorferi. Mol Microbiol (1990) 1.54
The variable antigens Vmp7 and Vmp21 of the relapsing fever bacterium Borrelia hermsii are structurally analogous to the VSG proteins of the African trypanosome. Mol Microbiol (1990) 1.52
Arthritis severity and spirochete burden are determined by serotype in the Borrelia turicatae-mouse model of Lyme disease. Infect Immun (1997) 1.51
Occupational lead poisoning in the United States: clinical and biochemical findings related to blood lead levels. Br J Ind Med (1979) 1.50
Structural analysis of the variable major proteins of Borrelia hermsii. J Exp Med (1983) 1.50
Borrelia burgdorferi mutant lacking Osp: biological and immunological characterization. Infect Immun (1995) 1.49
The role of interleukin 1 in human B cell activation: inhibition of B cell proliferation and the generation of immunoglobulin-secreting cells by an antibody against human leukocytic pyrogen. J Immunol (1983) 1.49
Coordinate modulation of D-glucose transport activity and bilayer fluidity in plasma membranes derived from control and insulin-treated adipocytes. Proc Natl Acad Sci U S A (1980) 1.45
Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins. J Clin Invest (2001) 1.44
Antigen diversity in the bacterium B. hermsii through "somatic" mutations in rearranged vmp genes. Cell (1994) 1.44
Immunologic and genetic analyses of VmpA of a neurotropic strain of Borrelia turicatae. Infect Immun (1997) 1.42
Action of penicillin on Borrelia hermsii. Antimicrob Agents Chemother (1982) 1.42
Comparative analysis and immunological characterization of the Borrelia Bdr protein family. Infect Immun (1999) 1.40
Population structure of the relapsing fever spirochete Borrelia hermsii as indicated by polymorphism of two multigene families that encode immunogenic outer surface lipoproteins. Infect Immun (1998) 1.40
Antibodies to Lyme-disease spirochaete in European lymphocytic meningoradiculitis (Bannwarth's syndrome) Lancet (1983) 1.39
Isolation of a spirochete from the soft tick, Ornithodoros coriaceus: a possible agent of epizootic bovine abortion. Science (1985) 1.39
The etiologic agent of Lyme disease in deer flies, horse flies, and mosquitoes. J Infect Dis (1986) 1.38
Bacteriophage in the Ixodes dammini spirochete, etiological agent of Lyme disease. J Bacteriol (1983) 1.38
Activation of a vmp pseudogene in Borrelia hermsii: an alternate mechanism of antigenic variation during relapsing fever. Mol Microbiol (1994) 1.36
Conversion of a linear to a circular plasmid in the relapsing fever agent Borrelia hermsii. J Bacteriol (1996) 1.31
A surface-exposed region of a novel outer membrane protein (P66) of Borrelia spp. is variable in size and sequence. J Bacteriol (1998) 1.30
Surface exposure and species specificity of an immunoreactive domain of a 66-kilodalton outer membrane protein (P66) of the Borrelia spp. that cause Lyme disease. Infect Immun (1996) 1.30
Male ticks help their mates to feed. Nature (1998) 1.29
Expression of the flagellin gene in Borrelia is controlled by an alternative sigma factor. Microbiology (1995) 1.29
STAT6 is required for IL-4-induced germline Ig gene transcription and switch recombination. J Immunol (1998) 1.27
Chemiluminescence by polymorphonuclear leukocytes from patients with active bacterial infection. J Infect Dis (1980) 1.26
Extensive interplasmidic duplications change the virulence phenotype of the relapsing fever agent Borrelia turicatae. Mol Microbiol (1999) 1.26
Clear, defined medium for the sporulation of Clostridium perfringens. Appl Environ Microbiol (1978) 1.25
Characterization of VspB of Borrelia turicatae, a major outer membrane protein expressed in blood and tissues of mice. Infect Immun (1999) 1.25